Gurgaon-based Ranbaxy Laboratories has emerged as the top pharmaceutical company, ahead of Cipla, in terms of market share in the Rs 36,000 crore domestic drug market for July.
During the month, Ranbaxy garnered 5.1 per cent market share with a growth of 13.4 per cent in terms of sales, according to stockist sales audit by ORG-IMS.
Cipla, which was ranked number two by the audit, had 4.89 per cent market share. It clocked a growth of 9.7 per cent during the month.
According to the audit, GlaxoSmithKline has the third biggest market share at 4.34 per cent. It managed a sales growth of 3.6 per cent.
Piramal Healthcare and Zydus Cadila were ranked at the fourth and the fifth position in July, with 3.90 per cent and 3.51 per cent market shares, respectively.
Zydus Cadila registered a growth of 11.6 per cent during the month while Piramal Healthcare expanded by 6.6 per cent, according to ORG-IMS audit.
The overall pharmaceutical market in the country recorded a growth of 10 per cent in July.
In the first three months of this calendar year Cipla occupied the top slot, while thereafter, Ranbaxy is holding the top position.
Ranbaxy captured 5.46 per cent market share in April followed by 5.24 per cent in May, 5.03 per cent in June and 5.10 per cent in July, against Cipla's market share of 5.40 per cent in April, 5.05 per cent in May, 4.93 per cent in June and 4.89 per cent in July.